LOS ANGELES, CALIFORNIA, July 26, 2023 (GLOBE NEWSWIRE) — MetAlert, Inc. (OTC: MLRT), a pioneer in location sensitive health monitoring devices and wearable technology products announced it has received a notice of allowance for a new patent by the European Patent Office (EPO). This will be the company’s first European utility patent in the GPS SmartSole family and will cover various ways to design, protect and manufacture a GPS, Cellular, Bluetooth and Wi-Fi monitoring electronic device embedded inside an insole including the inductive charging unit. This is the fifth patent granted to Metalert around tracking and monitoring devices within footwear with particular protection on the insole format.
“We have been working on this European patent for several years and we were very pleased to hear the news about the patent allowance. The timing could not have been better as we continue to roll out new generation GPS SmartSole products across Europe and North America. This new patent will provide us additional intellectual property protection in the major Western markets as well as key markets in Japan, S Korea, Australia, and New Zealand.” said Andrew Duncan Metalert Director.
“The patent has a large number of claims, with the opportunity to file additional divisional patents in the future and offers us protection against competition as well as possibly opening up new, oftentimes lucrative, licensing and partnership opportunities. While our ongoing investment in IP demonstrates MetAlert’s commitment to enhance our competitive barriers in the market, it also helps strengthen our overall value in the wearable tech industry,” stated Patrick Bertagna MetAlert CEO.
To find out more how you can buy or become an authorized reseller contact firstname.lastname@example.org business development.
Linked In: https://www.linkedin.com/company/metalertinc/
General information, investor relations, wholesale licensing, consumer purchase:
United Kingdom, London
Nelson Skip Riddle
Tel: +44 7785 364100
About MetAlert, Inc.:
MetAlert (OTC: MLRT) and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling, and licensing products, services, and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with Alzheimer, dementia, and autism. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software, and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC, and BLE technologies, enabling caregivers to track and monitor patients in real time. Known for its game-changing and award-winning patented GPS SmartSole® — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers across the globe with subscribers in over 40 countries and is a U.S. Military Government contractor. Other customers include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. www.MetAlert.com
This news release contains forward-looking statements. The terms and phrases “expects,” “would,” “will,” “believes,” and similar terms and phrases are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by MetAlert considering its experience and perception of current conditions and expected future developments, as well as other factors that MetAlert believes are appropriate in the circumstances. Many factors could cause MetAlert’s actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Certain risk factors that may cause actual results to differ are outlined in MetAlert’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (which may be obtained on the SEC Website). These factors should be considered carefully, and readers should not rely on MetAlert’s forward-looking statements. MetAlert has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required.
Disclaimer: MetAlert does not warrant or represent that the unauthorized use of materials drawn from this document’s content will not infringe the rights of third parties who are not owned or affiliated by MetAlert. Further, MetAlert cannot be held responsible or liable for the unauthorized use of this document’s content by third parties unknown to the company.
Source Globe Newswire